Media headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.8288583885642 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Spectrum Pharmaceuticals (SPPI) Raised to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Spectrum Pharma Inc (SPPI) Moves 0.11% – Clawson News (clawsonnews.com)
- As Spectrum Pharmaceuticals (SPPI) Share Price Declined, Consonance Capital Management LP Lifted Position … – Hill Country Times (hillcountrytimes.com)
- $33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter (americanbankingnews.com)
Spectrum Pharmaceuticals (SPPI) opened at $19.42 on Friday. The company has a market capitalization of $1,950.00, a P/E ratio of -19.42 and a beta of 1.63. Spectrum Pharmaceuticals has a 52 week low of $4.31 and a 52 week high of $21.95. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.89 and a current ratio of 5.04.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). The business had revenue of $36.40 million for the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.07) EPS. sell-side analysts forecast that Spectrum Pharmaceuticals will post -1.06 EPS for the current year.
Several equities research analysts have weighed in on the company. Guggenheim assumed coverage on Spectrum Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $32.00 price objective on the stock. Zacks Investment Research raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $29.00 price objective (up from $20.00) on shares of Spectrum Pharmaceuticals in a research note on Wednesday, October 18th. Jefferies Group upped their target price on Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a research note on Friday, October 20th. Finally, B. Riley started coverage on Spectrum Pharmaceuticals in a research note on Monday, December 18th. They set a “buy” rating and a $26.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.17.
TRADEMARK VIOLATION NOTICE: “Spectrum Pharmaceuticals (SPPI) Given Daily News Impact Rating of 0.12” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/14/spectrum-pharmaceuticals-sppi-given-daily-news-impact-rating-of-0-12.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.